Table 6.

Effect-to-treatment analysis: basic parameters

No	Study	NOP	mST	p Value	Rank	LMG	p Value	mNC	p Value	ETR (95% CI)	p Value	Rank
1	Brandes153	33	9.95 (7.73–12.17)	0.070	1	5.18 (2.79–7.56)	0.104	4.60 (3.87–5.33)	<0.001	1.13 (0.72 to 1.80)	0.273	2
2	Strik155	18	8.35 (7.67–9.03)	0.416	2	3.58 (1.98–5.17)	0.506	7.30 (6.05–8.55)	<0.001	0.49 (0.31 to 0.70)	0.001	6
3	Abacioglu156	16	6.98 (6.23–7.73)	0.345	6	2.20 (1.05–3.35)	0.486	3.33 (2.43–4.22)	0.004	0.66 (0.38 to 1.05)	0.022	3
4	Berrocal157	47	5.60 (4.16–7.04)	0.031	7	0.83 (−0.86–2.51)	0.073	4.55 (3.94–5.16)	<0.001	0.18 (−0.05 to 0.44)	<0.001	7
5	WA (1–4)	114	7.27 (6.30–8.24)	0.638	4	2.50 (1.20–3.80)	0.718	4.20 (3.82–4.57)	<0.001	0.59 (0.39 to 0.85)	0.006	4
6	WA (2–4)*	81	7.16 (6.25–8.08)	0.531	5	2.39 (1.13–3.65)	0.633	4.13 (3.68–4.57)	<0.001	0.58 (0.37 to 0.83)	0.005	5
7	Sahinbas23	54	7.63 (6.52–8.74)	1.000	3	2.85 (1.44–4.26)	1.000	1.56 (1.31–1.81)	1.000	1.83 (1.04 to 4.20)	1.000	1

*Main comparator.

LMG, life months gained; NOP, number of patients; WA, weighted average; mNC, mean number of cycles treated; mST, mean survival time since relapse.